---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-037423"
form_type: "8-K"
ticker: "PPCB"
cik: "0001517681"
company_name: "Propanc Biopharma, Inc."
filed_at: "2023-10-17T23:59:59+00:00"
generated_at: "2026-06-09T22:36:09.814305+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Propanc Biopharma issues $61K convertible note to GS Capital; conversion at $0.015, adjustable to $0.0075

## Summary
- Entered securities purchase agreement with GS Capital Partners, LLC for $61,000 principal convertible note at 8% interest.
- Note purchased at $57,500 ($3,500 OID); net proceeds for general working capital.
- Conversion price initially $0.015/share, reduced to $0.0075 if stock trades <$0.01 for 5+ consecutive trading days.
- Maturity April 12, 2024; prepayment options: 110% within 60 days, scaling to 125% by 180 days.
- Events of default include failure to timely issue conversion shares, loss of OTC listing, and non-compliance with SEC reporting.

## SEC filing metadata
- accession: 0001493152-23-037423
- form_type: 8-K
- ticker: PPCB
- cik: 0001517681
- company_name: Propanc Biopharma, Inc.
- filed_at: 2023-10-17T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517681/000149315223037423/0001493152-23-037423-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517681/000149315223037423/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-037423
- JSON: https://secwatch.observer/filing/0001493152-23-037423.json
- Plain text: https://secwatch.observer/filing/0001493152-23-037423.txt

## Key facts
- Debt Financings
  Propanc Biopharma, Inc. incurred convertible notes of $61,000 with an investor at 8% per annum maturing April 12, 2024.
  - Instrument: convertible notes
  - Principal: $61,000
  - Counterparty: an investor
  - Rate: 8% per annum
  - Maturity: April 12, 2024
  - Event: incurrence
  source text: On October 12, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible redeemable promissory note from the Company in the aggregate principal amount of $61,000 (the “Note”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223037423/0001493152-23-037423-index.htm
- Material Agreements
  Propanc Biopharma, Inc. entered into Purchase Agreement with Investor valued at $61,000 (effective 2023-10-12).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Investor
  - Value: $61,000
  - Effective: 2023-10-12
  source text: On October 12, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible redeemable promissory note from the Company in the aggregate principal amount of $61,000 (the “Note”), for a purchase price of $57,500.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223037423/0001493152-23-037423-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.